PBAC's latest decision on Escitalopram oxalate: Recommended with restriction (2008). Considered for Extension of listing to include moderate to severe social anxiety disorder (social phobia; SAD) in patients who have not responded to non-pharmacological therapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
$15k/QALY
—–$15k/QALY · across 2 submissions
Submissions
2
first 2008
Submissions
2
2008 → 2008
Eligible population
Adults with moderate to severe social anxiety disorder (social phobia; SAD) as defined by DSM-IV criteria who have not responded to non-pharmacological therapy.
Therapy area
Mental health
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Pivotal trial size
351 patients
Key trials
99270, 99012, 99269
Comparator
placebo
Economic model
CUA
Budget impact
$10M
Eligible patients/year
50,000
ICER note
PBAC noted the re-submission estimated the incremental cost per extra QALY gained to be less than $15,000; however, the PBAC acknowledged criticisms of the economic model and indicated the sensitivity analyses suggested a high probability the ICER would be acceptable rather than stating a precise figure.
ICER basis
Range aggregates 2 submissions (2008) — not a single base case.
Submission history
Mar 2008: Recommended with restriction · Restricted — ICER $15k/QALY
Mar 2008: Recommended with restriction · Restricted — ICER $15k/QALY